ウイルスベクターとプラスミドDNAの世界市場レポート 2025年

ウイルスベクターとプラスミドDNA市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で16億6,000万米ドルに成長します。予測期間の成長は、新たな治療への応用、COVID-19パンデミックへの対応、資金調達の増加、世界の拡大に起因しています。予測期間の主な動向には、ウイルスベクターおよびプラスミドDNA製造技術の進歩、遺伝子編集の進歩、カスタマイズベクター、拡張性および生産効率、安全性および品質基準、非ウイルス送達方法、国際協力などが含まれます。

世界のがん患者の急増は、ウイルスベクターおよびプラスミドDNA市場の成長の大きな原動力となっています。肥満、喫煙、飲酒、食生活の乱れといった一般的ながんの誘因は、がん診断の大部分に寄与しています。米国がん協会が2022年1月に予測したように、米国では同年、190万人の新規がん患者と約60万9,360人のがん関連死が発生する可能性が高いです。世界的には、肺がん、前立腺がん、腸がん、女性の乳がんが最も多く、新規がん患者全体の43％を占めています。このようながん罹患率の増加は、市場におけるウイルスベクターとプラスミドDNAの需要を強化すると予想されます。

結核患者の増加も、ウイルスベクターおよびプラスミドDNA市場の成長を促進しています。結核は細菌によって引き起こされる感染症であり、主に肺を侵すが、他の身体部位に及ぶこともあります。プラスミドDNAワクチンは、結核の微生物抗原をコードする遺伝子を送達するもので、この病気と闘う上で有望視されています。これらのワクチンは、筋肉内注射によって原因菌である結核菌の特異的抗原を発現させることができます。米国疾病予防管理センターの2023年3月の報告書によると、米国では結核患者が2021年の7,874人から2022年には8,300人に増加しており、ウイルスベクターとプラスミドDNA市場の成長における結核患者の原動力が強調されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ウイルスベクターとプラスミドDNA PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のウイルスベクターとプラスミドDNA市場：成長率分析
• 世界のウイルスベクターとプラスミドDNA市場の実績：規模と成長, 2019-2024
• 世界のウイルスベクターとプラスミドDNA市場の予測：規模と成長, 2024-2029, 2034F
• 世界ウイルスベクターとプラスミドDNA総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のウイルスベクターとプラスミドDNA市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラスミドDNA
• ウイルスベクター
• 世界のウイルスベクターとプラスミドDNA市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 感染症
• 遺伝性疾患
• がん
• その他の病気
• 世界のウイルスベクターとプラスミドDNA市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子およびがん治療
• ウイルス感染
• 免疫療法
• 処方開発
• その他の用途
• 世界のウイルスベクターとプラスミドDNA市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 調査機関
• バイオ医薬品および製薬会社
• 世界のウイルスベクターとプラスミドDNA市場プラスミドDNAのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 研究グレードのプラスミドDNA
• 臨床グレードのプラスミドDNA
• GMP（適正製造基準）プラスミドDNA
• 世界のウイルスベクターとプラスミドDNA市場ウイルスベクターの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アデノウイルスベクター
• レンチウイルスベクター
• AAV（アデノ随伴ウイルス）ベクター
• レトロウイルスベクター
• 水疱性口内炎ウイルス（VSV）ベクター

第7章 地域別・国別分析

• 世界のウイルスベクターとプラスミドDNA市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のウイルスベクターとプラスミドDNA市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ウイルスベクターとプラスミドDNA市場：競合情勢
• ウイルスベクターとプラスミドDNA市場：企業プロファイル
  • FUJIFILM Diosynth Biotechnologies Overview, Products and Services, Strategy and Financial Analysis
  • FinVector Vision Therapies Overview, Products and Services, Strategy and Financial Analysis
  • Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • Cobra Biologics and Pharmaceutical Services Overview, Products and Services, Strategy and Financial Analysis
  • Brammer Bio Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Kaneka Corporation
• Cell and Gene Therapy Catapult
• VGXI Inc.
• MassBiologics
• Sanofi
• Spark Therapeutics
• UniQure NV
• Thermo Fisher Scientific
• VIROVEK
• SIRION Biotech GmbH
• ALDEVRON
• Oxford BioMedica
• PlasmidFactory GmbH & Co. KG
• Biovian Oy
• BioReliance Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ウイルスベクターとプラスミドDNA市場2029：新たな機会を提供する国
• ウイルスベクターとプラスミドDNA市場2029：新たな機会を提供するセグメント
• ウイルスベクターとプラスミドDNA市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Viral vectors are tools constructed from viral genomes adapted into plasmid-based technologies. They are modified for safety by removing specific essential genes and separating viral components. On the other hand, plasmid DNA refers to small, circular DNA molecules present in certain bacteria and other microorganisms. These plasmids are physically distinct from chromosomal DNA and can replicate independently.

The primary product types within the viral vectors & plasmid DNA domain include plasmid DNA and viral vectors. Plasmids are circular DNA molecules separate from a cell's chromosomal DNA, commonly found in bacterial and some eukaryotic cells. Plasmid genes often confer genetic advantages to bacteria, such as antibiotic resistance.

The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The viral vectors and plasmid dna market size has grown rapidly in recent years. It will grow from $1.05 billion in 2024 to $1.2 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing prevalence of cancer, growing awareness of gene therapy, growing patient population, increased access to healthcare, growing demand for personalized medicine.

The viral vectors and plasmid dna market size is expected to see strong growth in the next few years. It will grow to $1.66 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to emerging therapeutic applications, COVID-19 pandemic response, increased funding, global expansion. Major trends in the forecast period include advances in viral vector and plasmid DNA manufacturing technology, advances in gene editing, customized vectors, scalability and production efficiency, safety and quality standards, non-viral delivery methods, international collaboration.

The global surge in cancer cases is a significant driving force behind the growth of the viral vector and plasmid DNA market. Common cancer triggers like obesity, smoking, alcohol consumption, and poor dietary habits contribute to the majority of cancer diagnoses. As projected by the American Cancer Society in January 2022, the US will likely witness 1.9 million new cancer cases and approximately 609,360 cancer-related deaths in the same year. Globally, lung, prostate, bowel, and female breast cancers are the most prevalent, accounting for 43% of all new cancer cases. This rise in cancer incidence is anticipated to bolster the demand for viral vectors and plasmid DNA in the market.

The increasing prevalence of tuberculosis cases is also driving growth in the viral vector and plasmid DNA market. Tuberculosis, an infectious disease caused by bacteria, primarily affects the lungs but can extend to other body parts. Plasmid DNA vaccines, delivering microbial antigen-coding genes for tuberculosis, have shown promise in combating this disease. These vaccines can express specific antigens of Mycobacterium tuberculosis, the causative bacterium, through intramuscular injection. According to the Centers for Disease Control and Prevention's March 2023 report, the US witnessed a rise in tuberculosis cases from 7,874 in 2021 to 8,300 in 2022, emphasizing the driving force of tuberculosis cases in the growth of the viral vector and plasmid DNA market.

Companies in the viral vectors and plasmid DNA market are strategically launching viral vector assays to invigorate gene therapy research. Viral vectors, essential in delivering genetic material into cells, are complemented by viral vector assays, investigative procedures that analyze these vectors. For instance, in November 2022, PerkinElmer introduced 'ready-to-use' adeno-associated virus vectors (AAV) detection kits. These aids support researchers involved in gene therapy across diverse diseases by facilitating the quick and efficient characterization of viral vector particles, guiding safe and effective gene transfer decisions.

Major players in the viral vectors and plasmid DNA market are intensifying their efforts toward product innovation, notably helper plasmids, to gain a competitive edge. Helper plasmids, a form of plasmid DNA utilized in producing viral vectors like adeno-associated viral vectors (AAV), are pivotal in gene therapy. For instance, Charles River Laboratories International Inc. unveiled off-the-shelf pHelper in March 2023. This innovation streamlines the process of developing adeno-associated virus (AAV)-based gene therapy programs, minimizing complexities and expediting supply chains. pHelper, part of a comprehensive line of contract development and manufacturing organization (CDMO) offerings, serves to fortify viral vector packaging in cell and gene therapy endeavors, particularly in creating adeno-associated viral vectors essential for gene therapy.

In January 2023, Moderna Inc., a pharmaceutical and biotechnology company based in the US, finalized the acquisition of OriCiro Genomics for $85 million. This strategic acquisition aims to expedite Moderna's pipeline development by enhancing their capabilities in plasmid DNA synthesis and amplification, which serves as a crucial foundation for manufacturing messenger RNA (mRNA). OriCiro Genomics, a Japan-based genome technology company, specializes in developing and commercializing cell-free systems designed for assembling and amplifying circular DNA molecules, notably plasmids and viral vectors. This acquisition positions Moderna to strengthen its mRNA production processes with advanced tools provided by OriCiro Genomics.

Major companies operating in the viral vectors and plasmid dna market include FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Kaneka Corporation, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, Mylan NV, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

North America was the largest region in the viral vectors and plasmid DNA market in 2024. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the viral vectors and plasmid dna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Vectors And Plasmid DNA Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on viral vectors and plasmid dna market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral vectors and plasmid dna ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral vectors and plasmid dna market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Plasmid DNA; Viral Vectors
• 2) By Disease: Infectious Diseases; Genetic Disorders; Cancer; Other Diseases
• 3) By Application: Gene And Cancer Therapies; Viral Infections; Immunotherapy; Formulation Development; Other Applications
• 4) By End User: Research Institutes; Biopharmaceutical And Pharmaceutical Companies
• Subsegments:
• 1) By Plasmid DNA: Research-Grade Plasmid DNA; Clinical-Grade Plasmid DNA; GMP (Good Manufacturing Practice) Plasmid DNA
• 2) By Viral Vectors: Adenoviral Vectors; Lentiviral Vectors; AAV (Adeno-Associated Virus) Vectors; Retroviral Vectors; Vesicular Stomatitis Virus (VSV) Vectors
• Companies Mentioned: FUJIFILM Diosynth Biotechnologies; FinVector Vision Therapies; Lonza Group AG; Cobra Biologics and Pharmaceutical Services; Brammer Bio
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Viral Vectors And Plasmid DNA Market Characteristics

3. Viral Vectors And Plasmid DNA Market Trends And Strategies

4. Viral Vectors And Plasmid DNA Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Viral Vectors And Plasmid DNA Growth Analysis And Strategic Analysis Framework

• 5.1. Global Viral Vectors And Plasmid DNA PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Viral Vectors And Plasmid DNA Market Growth Rate Analysis
• 5.4. Global Viral Vectors And Plasmid DNA Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Viral Vectors And Plasmid DNA Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Viral Vectors And Plasmid DNA Total Addressable Market (TAM)

6. Viral Vectors And Plasmid DNA Market Segmentation

• 6.1. Global Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasmid DNA
• Viral Vectors
• 6.2. Global Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infectious Diseases
• Genetic Disorders
• Cancer
• Other Diseases
• 6.3. Global Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene And Cancer Therapies
• Viral Infections
• Immunotherapy
• Formulation Development
• Other Applications
• 6.4. Global Viral Vectors And Plasmid DNA Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Research Institutes
• Biopharmaceutical And Pharmaceutical Companies
• 6.5. Global Viral Vectors And Plasmid DNA Market, Sub-Segmentation Of Plasmid DNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Research-Grade Plasmid DNA
• Clinical-Grade Plasmid DNA
• GMP (Good Manufacturing Practice) Plasmid DNA
• 6.6. Global Viral Vectors And Plasmid DNA Market, Sub-Segmentation Of Viral Vectors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenoviral Vectors
• Lentiviral Vectors
• AAV (Adeno-Associated Virus) Vectors
• Retroviral Vectors
• Vesicular Stomatitis Virus (VSV) Vectors

7. Viral Vectors And Plasmid DNA Market Regional And Country Analysis

• 7.1. Global Viral Vectors And Plasmid DNA Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Viral Vectors And Plasmid DNA Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Viral Vectors And Plasmid DNA Market

• 8.1. Asia-Pacific Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Viral Vectors And Plasmid DNA Market

• 9.1. China Viral Vectors And Plasmid DNA Market Overview
• 9.2. China Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Viral Vectors And Plasmid DNA Market

• 10.1. India Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Viral Vectors And Plasmid DNA Market

• 11.1. Japan Viral Vectors And Plasmid DNA Market Overview
• 11.2. Japan Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Viral Vectors And Plasmid DNA Market

• 12.1. Australia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Viral Vectors And Plasmid DNA Market

• 13.1. Indonesia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Viral Vectors And Plasmid DNA Market

• 14.1. South Korea Viral Vectors And Plasmid DNA Market Overview
• 14.2. South Korea Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Viral Vectors And Plasmid DNA Market

• 15.1. Western Europe Viral Vectors And Plasmid DNA Market Overview
• 15.2. Western Europe Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Viral Vectors And Plasmid DNA Market

• 16.1. UK Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Viral Vectors And Plasmid DNA Market

• 17.1. Germany Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Viral Vectors And Plasmid DNA Market

• 18.1. France Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Viral Vectors And Plasmid DNA Market

• 19.1. Italy Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Viral Vectors And Plasmid DNA Market

• 20.1. Spain Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Viral Vectors And Plasmid DNA Market

• 21.1. Eastern Europe Viral Vectors And Plasmid DNA Market Overview
• 21.2. Eastern Europe Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Viral Vectors And Plasmid DNA Market

• 22.1. Russia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Viral Vectors And Plasmid DNA Market

• 23.1. North America Viral Vectors And Plasmid DNA Market Overview
• 23.2. North America Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Viral Vectors And Plasmid DNA Market

• 24.1. USA Viral Vectors And Plasmid DNA Market Overview
• 24.2. USA Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Viral Vectors And Plasmid DNA Market

• 25.1. Canada Viral Vectors And Plasmid DNA Market Overview
• 25.2. Canada Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Viral Vectors And Plasmid DNA Market

• 26.1. South America Viral Vectors And Plasmid DNA Market Overview
• 26.2. South America Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Viral Vectors And Plasmid DNA Market

• 27.1. Brazil Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Viral Vectors And Plasmid DNA Market

• 28.1. Middle East Viral Vectors And Plasmid DNA Market Overview
• 28.2. Middle East Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Viral Vectors And Plasmid DNA Market

• 29.1. Africa Viral Vectors And Plasmid DNA Market Overview
• 29.2. Africa Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Viral Vectors And Plasmid DNA Market Competitive Landscape And Company Profiles

• 30.1. Viral Vectors And Plasmid DNA Market Competitive Landscape
• 30.2. Viral Vectors And Plasmid DNA Market Company Profiles
  • 30.2.1. FUJIFILM Diosynth Biotechnologies Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. FinVector Vision Therapies Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cobra Biologics and Pharmaceutical Services Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Brammer Bio Overview, Products and Services, Strategy and Financial Analysis

31. Viral Vectors And Plasmid DNA Market Other Major And Innovative Companies

• 31.1. Kaneka Corporation
• 31.2. Cell and Gene Therapy Catapult
• 31.3. VGXI Inc.
• 31.4. MassBiologics
• 31.5. Sanofi
• 31.6. Spark Therapeutics
• 31.7. UniQure NV
• 31.8. Thermo Fisher Scientific
• 31.9. VIROVEK
• 31.10. SIRION Biotech GmbH
• 31.11. ALDEVRON
• 31.12. Oxford BioMedica
• 31.13. PlasmidFactory GmbH & Co. KG
• 31.14. Biovian Oy
• 31.15. BioReliance Corporation

32. Global Viral Vectors And Plasmid DNA Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Viral Vectors And Plasmid DNA Market

34. Recent Developments In The Viral Vectors And Plasmid DNA Market

35. Viral Vectors And Plasmid DNA Market High Potential Countries, Segments and Strategies

• 35.1 Viral Vectors And Plasmid DNA Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Viral Vectors And Plasmid DNA Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Viral Vectors And Plasmid DNA Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer